US biotech major Amgen announced financial results for the second quarter of 2025 after market closed on Tuesday, with ...

A preclinical biotech company based in Wilmington, Delaware, focused on developing CAR‑T cell immunotherapies to treat severe ...

The UK’s National Institute for Health and Care Excellence (NICE) on August 6 recommended the use of US pharma giant Merck & ...

Pfizer posted second-quarter 2025 earnings and revenue that exceeded analyst estimates and raised its full-year profit ...

US cardiometabolic specialist MetaVia has announced a research collaboration with Korea’s Syntekabio, an artificial ...

Russia is currently experiencing a boom in the sales of Ozempic (semaglutide) and its analogues due to a high demand for such drugs among domestic customers, reports The Pharma Letter’s local ...

Japanese drugmaker Sumitomo Pharma Company and Tokyo-based Racthera announced that on August 5, they had submitted an ...

XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday.

Texas, USA-based Nanoscope Therapeutics has recently submitted a rolling biologics license application (BLA) to the Food and ...

Hungary’s largest drugmaker Gedeon Richter has announced the UK launch of Nalvee (10mg dydrogesterone), a highly bioavailable oral progestogen tablet for hormone replacement therapy (HRT).

The UK’s National Health Service (NHS) and local authorities have started the rollout of world-first gonorrhoea vaccination ...

Privately-held US clinical-stage biotech Cellergy Pharma announced the appointment Christopher Cano as chief executive (CEO).